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ABSTRACT
Anaphylaxis is defined as an acute severe, life-threatening hypersensitivity reaction. The condition’s real prevalence and incidence are 
difficult to estimate, but seem to be increasing, particularly in children. Anaphylaxis clinical presentation varies according to age and other 
individual factors.  Although consensual clinical criteria exist, including in pediatric age, diagnosis can be challenging. Food allergy is the most 
common anaphylaxis cause in children, particularly in preschool age. Drug-induced reactions and hymenoptera venom sting are other major 
triggers, which importance increases after adolescence. Management involves diagnosis, appropriate identification of possible triggers, acute 
phase treatment, and long-term planning. Prompt referral to a Pediatric Allergy specialist is recommended, as complete allergy workup is 
usually required to implement future preventive measures. In this review, the authors discuss particular aspects regarding anaphylaxis in 
pediatric age to provide information that can help improve disease management.
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RESUMO
A anafilaxia define-se como uma reação de hipersensibilidade aguda grave, que pode estar associada a risco de vida. A sua prevalência e 
incidência são difíceis de estimar, mas parecem estar a aumentar, sobretudo na faixa etária pediátrica. A apresentação clínica da anafilaxia 
varia de acordo com a idade e fatores individuais. Apesar de existirem critérios clínicos já estabelecidos, inclusive em idade pediátrica, o 
diagnóstico desta entidade pode ser difícil. A alergia alimentar é a causa mais comum de anafilaxia em idade pediátrica, especialmente 
em idade pré-escolar. As reações desencadeadas por fármacos e por veneno de himenópteros são também importantes, sendo que a sua 
relevância vai aumentado depois da adolescência. A abordagem desta condição envolve o diagnóstico, identificação apropriada dos agentes 
implicados, tratamento de fase aguda e planificação da abordagem a longo prazo. A referenciação rápida para um Imunoalergologista é 
recomendada, uma vez que o estudo alergológico é fundamental para a implementação de medidas preventivas. Nesta revisão, os autores 
discutem aspetos da anafilaxia em idade pediátrica, com o objetivo de fornecer informação que possa otimizar a abordagem desta entidade. 
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INTRODUCTION
Anaphylaxis is a clinical emergency that should be promptly 
recognized to avoid acute treatment delays. The most commonly 
used anaphylaxis grading classification was proposed by Ring and 
Messmer1 and considers four grades, with grade IV accounting for 
the most serious reactions with respiratory or cardiovascular arrest. 
Several criteria have been established to help diagnosis and classify 
disease severity. However, diagnosis can be challenging, and this is 
particularly true in pediatric age. All patients should be referred to 
formal workup to identify potentially avoidable triggers and prevent 
future reactions. Most common triggers vary between adults and 
children and this should be considered during diagnostic workup.
In this article, the authors review current anaphylaxis general 
concepts and focus on specific pediatric aspects of diagnosis, 
management, and treatment.
EPIDEMIOLOGY
Anaphylaxis is defined as an acute, potentially life threatening 
systemic hypersensitivity reaction occurring without warning.2–4 
Although major efforts have been done over the last decades to 
establish an unanimous case definition and diagnostic criteria, 
implementation of a standardized clinical practice approach remains 
a significant challenge.5 As a consequence, underdiagnosis and 
underreporting remain well-acknowledged problems. Additionally, 
tools currently used to report anaphylaxis (ICD-9, ICD-10, and ICD-
11) still lack sensitivity and specificity. 
Anaphylaxis epidemiological data is retrieved from several sources, 
including Emergency Departments (EDs), regional and national 
databases, and health organizations.6
The real prevalence and incidence of pediatric anaphylaxis are 
difficult to estimate. In 2006, the National Institute of Allergy and 
Infectious Disease and the Food Allergy and Anaphylaxis Network 
(NIAID-FAAN) established criteria for diagnosis of anaphylaxis, after 
which several studies have been published, including regarding 
anaphylaxis incidence and prevalence in pediatric age.5,7–16
Based on recent publications, the estimated overall anaphylaxis 
incidence ranges between 50−112 episodes per 100.000 person-
years, and the estimated prevalence between 0.3−5.1%.6 Lifetime 
anaphylaxis prevalence has been estimated to vary between 
0.5−2%.16
In Sweden, a population-based case study of ED visits examined 
385 records of children aged 0−18 years and estimated a total food 
anaphylaxis incidence of 32 per 100.000 person-years in this age 
group.15 In a Spanish study conducted by Alonso T et al including 
325.046 people, a peak incidence of 313.58 per 100.000 person-years 
was reported in the 0−4-year-old age group, which was significantly 
higher (p <0.05) compared with other age groups.8 In the UK, a review 
of 816 of 401.152 (0.2%) ambulance calls due to anaphylaxis revealed 
that 180 (22%) cases occurred in children.17
Incidence, prevalence, and relevance of anaphylaxis triggers seem 
to vary according to age, gender, geographic area, healthcare access, 
among other factors. While foods are the most commonly implicated 
anaphylaxis triggers in young children, drugs are consistently found 
to be the most frequent triggers in adolescents and adults.6,18–21 
The European Anaphylaxis Registry resulted from a multicenter study 
conducted in 10 European countries which analysed information 
on anaphylactic reactions through a web-based data entry system 
including 1970 anaphylaxis events in pediatric patients (1865 with 
known elicitors). The study found that foods were the most common 
elicitors (69.2%), followed by hymenoptera stings (20.4%) and drugs 
(5.4%).12 Drugs accounted for only 3.1% of anaphylaxis events in 
preschoolers aged <6 years, 4.1% in children aged 6−12 years, and 
12.1% in adolescents aged 13−17 years. Analgesics were the most 
frequently implicated drugs.12
Among children, males seem to be particularly affected, as they 
represent 57−70% of all pediatric cases, but among adults, women 
are more prone to suffer from an anaphylactic event.13,22,23 Pre-school 
children (0−4 years) seem to be more affected, with a threefold higher 
incidence compared with other age groups, as recently reported in 
one Spanish and one Australian study.7,24
Fatal anaphylaxis in pediatric age seems to be rare.5,12,25,26 As 
described by Liew et al, death from anaphylaxis is generally preceded 
by non-fatal anaphylaxis.26 The most frequent elicitors in fatal cases 
are foods, especially cow milk, hazelnut, and peanut.6 According 
to European Anaphylaxis Registry data, approximately 1.3% (26 in 
1970) of children in pediatric age experienced life-threatening or 
fatal reactions, all having food as trigger: 11 experienced Ring and 
Messmer classification grade III reactions with Intensive Care Unit 
(ICU) admission; 10 experienced grade IV symptoms, three of which 
requiring ICU admission, one requiring treatment by a family member 
and another by an emergency doctor, and five with no information; 
and five died.12
ED visits and hospitalizations due to anaphylaxis seem to be 
increasing over the last decade, including in children.9 In Spain, a 
1.89-fold increase in anaphylactic events was reported between 
1998−2011, particularly among children under 14 years of age.27 In 
the USA, a recent study reported a fourfold increase in emergency 
admissions and in the UK admission rates increased from 0.5 
to 3.6/100.000 persons per year between 1991 and 2001.24,28 
In Australia, an analysis comparing 1993−1994 and 2004−2005 
anaphylaxis events found an increase from 4.5 to 8.2/100.000 
persons per year, which was particularly prominent in children aged 
between 5−14 years old.29 
Causative agents and risk factors
According to last findings from the European Anaphylaxis Registry, 
food-induced anaphylaxis is the most common entity in children 
and adolescents, accounting for 66% of cases. Other less frequent 
causes include insect bites/stings (19%) and drug allergy (5%). 
Relevance of each trigger varies according to age; for example, 88% 
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of preschoolers suffer from food-induced anaphylaxis, followed 
by 13% with drug-induced anaphylaxis, and 7% with insect sting 
bite anaphylaxis. Relevance of drug-induced and insect sting bite 
anaphylaxis increases with age, accounting for 22% and 16% 
of adolescent cases, respectively.12 Anaphylaxis due to specific 
aeroallergen immunotherapy administration has also been reported, 
with a predictable increase  in the number of iatrogenic anaphylaxis 
events with the increasing number of food desensitization 
protocols.20,30–32 The first European case of fatal anaphylaxis during 
an oral food challenge involved a three-year-old boy and occurred in 
2017.33 Anaphylaxis from non-immunologic triggers is less common, 
but cases have been reported associated with cold, exercise, heat, 
and some medications such as opioids.34 In children, cold anaphylaxis 
is an important event that should be considered. It was reported in 
two Portuguese studies, with a significant 1.4−4.6% prevalence.11,35 
Cold anaphylaxis seems to be present in one third of patients with 
cold-induced urticaria.36
Several reports suggest that approximately 20% of all anaphylaxis 
episodes are idiopathic.5
The main acknowledged risk factors and cofactors associated with 
anaphylaxis in pediatric age are described in Table 1. 
Table 1 - Factors and cofactors associated with increased risk of 
serious anaphylaxis and mortality.  Adapted from Muraro A, et al and 
Simons EF, et al.2,37
Lifestyle factors Physical exercise
Alcohol
Drugs NSAIDs
ACE inhibitors
B-blockers
Patient-specific 
factors
Breastfed infants - difficulty in recognizing 
anaphylaxis leads to underdiagnosis
Adolescents and young people – increase in risk 
behaviors
Infections (e.g.: upper respiratory tract infection)
Hormonal status (e.g.: menstrual period)
Anxiety/stress
Comorbidities Asthma and other respiratory diseases, 
especially if severe or not controlled
Cardiovascular disease
Systemic mastocytosis
Allergic rhinitis and eczema
Psychiatric diseases
Thyroid gland diseases
Other factors Previous history of anaphylaxis
Increased basal levels of histamine and tryptase
ACE, angiotensin-converting enzyme; NSAID, nonsteroidal anti-
inflammatory drug
RESULTS
In pediatric populations, the main risk factors and cofactors 
associated with an increased anaphylaxis mortality risk are coexisting 
asthma − especially if severe or uncontrolled − and history of previous 
anaphylactic reactions.37,38
Cofactors such as physical exertion and nonsteroidal anti-
inflammatory drug (NSAID) and/or alcohol intake have been 
associated with more serious events and can be particularly important 
among adolescents. Anaphylaxis associated with food intake in the 
context of physical exercise should be considered within the frame 
of a special entity, known as food-dependent exercise-induced 
anaphylaxis (FDEIA). In FDEIA, anaphylaxis onset during exercise is 
preceded by ingestion of the causal food allergen(s), while both food 
allergen ingestion and exercise are tolerated if done independently. 
Although uncommon, this diagnosis should be considered in cases of 
suggestive exercise-induced anaphylaxis.39
Clinical presentation and diagnosis
Although anaphylaxis definition is virtually unanimous, diagnosis 
is essentially clinical and diagnostic criteria vary according to 
different guidelines.2,5,37,38,40 It is a concern that many physicians 
still fail to recognize anaphylaxis and diagnose the condition and to 
evaluate its severity. A study conducted by Thomson et al evaluated 
ED presentation of 60.143 pediatric patients and identified 1.551 
allergy-related episodes. Among those, 211 anaphylaxis events were 
identified (0.35% of all ED and 13.6% of ED allergy-related visits), but 
anaphylaxis diagnosis in ED was only established for 105 cases, the 
remaining 106 receiving an alternative diagnosis. The authors further 
identified 24 episodes that were classified as anaphylaxis without 
meeting established diagnostic criteria.41
This highlights the need of standardizing anaphylaxis clinical criteria 
as well as improving knowledge of healthcare professionals dealing 
with the condition.42
Primary diagnostic criteria include acute skin onset and/or 
mucosal symptoms, along with either respiratory compromise (e.g.: 
bronchospasm, stridor, shortness of breath), and/or gastrointestinal 
symptoms (e.g.: crampy abdominal pain, vomiting), and/or reduced 
blood pressure or end-organ dysfunction-associated symptoms (e.g.: 
hypotonia, syncope, incontinence).20 In cases of serum tryptase 
elevation, diagnosis may be supported within a few hours after 
reaction compared with patient baseline levels; however, in children, 
particularly with food-triggered reactions, levels are often normal.43
Three clinical scenarios should be considered when establishing an 
anaphylaxis diagnosis, which are described in Algorithm 1.1,4
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Clinical history is the most important tool for diagnosis and etiology 
determination. 
In a 2012 study describing a cohort of pediatric and adult anaphylaxis 
patients from Central Europe (German, Austria, and Switzerland), 
skin involvement was the most frequently reported symptom 
(84%), followed by cardiovascular symptoms (72%), and respiratory 
symptoms (68%).44 Another study reported clinical anaphylaxis 
manifestations according to age in a group of 605 children evaluated 
at ED for a period of six years. Although skin involvement is not 
mandatory in anaphylactic reactions, study authors found that it was 
predominant (≥85%) in all age groups (infancy, preschool age, school 
age, and adolescence).45
More than 50% of children presented with gastrointestinal 
symptoms and respiratory symptoms were present in more than 
70% of cases, being particularly prevalent in preschool age (around 
80%).35,46
Complete anamnesis is necessary in the diagnostic approach: 
symptom onset time, place/environment where the reaction 
occurred, number and characterization of past episodes, administered 
treatments, and all suspected causes and possible cofactors at the 
time of the episode.14,47 Dietary and drug intake, hymenoptera sting 
bite, latex contact, physical activity, and factors as cold, heat, and 
alcohol intake should always be investigated.14,38
Anaphylaxis diagnosis in infants can be challenging, and this difficulty 
may be related to several factors: difficulty in expressing complaints/
describing signs; subjectivity in identifying signs and symptoms 
as part of anaphylaxis clinical presentation (e.g.: pruritus, nasal 
congestion, abdominal cramps or nausea, regurgitation, diarrhea, 
irritability, hoarseness, and dysphonia); and presence of easily 
recognizable but non-specific signs, such as generalized urticaria, 
sudden respiratory symptoms (e.g.: cough, choking and wheezing), or 
altered consciousness.48,49 In infants, recurrent vomiting, irritability, 
persistent crying and hypotonia, and hyporresponsiveness can be 
part of initial anaphylaxis presentation. Simple findings as irritability 
may correspond to cardiovascular system involvement in anaphylaxis 
in infants.46
Cardiovascular evaluation, including blood pressure and capillary 
refill time measurement, during anaphylaxis episodes seems to 
be neglected, particularly in infants, possibly due to difficulty in 
evaluating blood pressure in a crying and irritable infant. 13,46 
Factors as availability of appropriate-sized sphygmomanometer cuffs 
for infants may also be decisive.46
Symptoms are more specific in older children and adolescents, with 
cutaneous symptoms predominance, followed by respiratory and 
gastrointestinal manifestations.32,46
However, most fatal anaphylaxis events occur during adolescence, 
what can be partially explained by factors as less caregiver supervision, 
lack of responsibility and risk-taking behaviors.40,50,51 Cardiovascular 
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symptoms seem to be more frequent (12%) in adolescents compared 
with children.45 Additionally, also exercise-related anaphylaxis 
(dependent or not on food ingestion) is more frequent at this age.37
The place where anaphylaxis episodes take place varies. Most occur 
at home, almost 30% on the outside, and 10−18% of allergic food 
reactions occur at school.35,52
Anaphylaxis diagnosis should be considered in all age groups 
and both acute urticaria and asthma attack should be considered 
in the differential diagnosis.2  In infants and preschoolers, 
respiratory distress is a common manifestation of several 
respiratory infections, like laryngitis, bronchiolitis, and foreign body 
aspiration. Gastrointestinal symptoms may be explained by several 
gastrointestinal conditions, including acute gastroenteritis, intestinal 
intussusception, appendicitis, protein-induced enterocolitis, and 
many others. Regarding neurological symptoms, seizures, post-ictal 
state, traumatic head injury, drug intoxication, and metabolic disease 
should be taken into account in differential diagnosis.48,49 Other 
important differential diagnoses, especially among adolescents, are 
panic attacks and vasovagal reactions, which can be accompanied 
by hypotension and are commonly associated with pallor and 
diaphoresis.14,38 
Anaphylaxis emergency management 
Anaphylaxis is a clinical emergency and healthcare professionals 
should be familiar with its recognition and management. Patients 
require immediate assessment using an Airway, Breathing, 
Circulation, Disability, and Exposure (ABCDE) approach. First-
line treatment consists of intramuscular (IM) epinephrine and 
should be administered to all patients experiencing anaphylaxis. 
Epinephrine acts as an alpha- and beta-adrenergic agonist, resulting 
in vasoconstriction and decreased mucosal edema. It has positive 
inotropic and chronotropic effects and induces bronchodilation and 
decreased mediator release from mast cells and basophils.37,53 In 
children, recommended epinephrine dose is 0.01 mg/kg (maximum 
0.5 mg) of a 1:1000 (1 mg/mL) solution via IM injection into the mid-
anterolateral thigh.14
Auto-injector epinephrine dosing is 0.15 mg for children weighing 
10–25 kg and 0.3 mg for those weighing >25 kg.54 Repeated doses 
after five minutes are recommended in cases of suboptimal response 
or symptom progression.14,54 Intravenous epinephrine infusion 
or bolus should be considered in specific circumstances, such as 
severely hypotensive patients, patients in cardiac or respiratory 
arrest (together with cardiorespiratory resuscitation), and patients 
failing to respond to multiple IM epinephrine injections. In such 
cases, continuous hemodynamic monitoring is mandatory.14 Patients 
may experience self-limited adverse effects after epinephrine 
administration, such as pallor, tremor, anxiety, palpitations, dizziness, 
and headaches. 
Second-line intervention 
If possible, the likely anaphylaxis trigger should be immediately 
removed and help requested from the hospital emergency services 
or resuscitation team.37 Although it is generally recommended to 
place the patient in a recumbent position with lower extremities 
elevated, individuals experiencing respiratory distress (common 
in children) or vomiting should instead be placed in a comfortable 
position.2 Supplemental oxygen should be administered by face mask 
or oropharyngeal airway at a 6-8 L/min flowrate. Fluid administration 
with normal saline is also an appropriate starting measure. Children 
in shock may require up to 30 mL/kg of saline solution in the first 
hour.2,55 Although inhaled bronchodilators and inhaled nebulized 
adrenaline may be used as adjuncts for lower airway symptoms, they 
are not recommended in anaphylaxis for not relieving upper airway 
constriction or shock.51
H1-antihistamines are not recommended as initial anaphylaxis 
treatment because, despite decreasing urticaria and itching, they do 
not relieve life-threatening respiratory symptoms or shock. Although 
glucocorticoids can be used,  as they potentially prevent biphasic 
anaphylaxis, their action onset takes hours and therefore are not 
drugs of choice for initial anaphylaxis treatment.2 
After acute anaphylaxis therapy, patients should be kept under 
surveillance: those presenting with respiratory compromise should 
be closely monitored for at least 6–8 hours, and those presenting 
with hypotension for at least 12–24 hours. One of the reasons for 
maintaining monitoring is the occurrence of biphasic reactions in 
1−23% of cases.37 In pediatric populations, the reported incidence of 
biphasic reactions is lower (up to 11%) and most biphasic reactions 
seem to be either milder or of similar severity compared with 
the original presentation, but there are no reliable methods for 
predicting biphasic reactions.56 Factors that have been implicated 
in development of biphasic reactions include absence or delay of 
epinephrine administration during initial anaphylactic reaction, 
initial event severity (receiving >1 epinephrine dose), and slow 
initial reaction resolution. Failure to administer corticosteroids 
may predispose to a biphasic response, although this has not been 
categorically shown. To date, no study has reported prior anaphylaxis 
history or presence of asthma or specific allergen triggers as factors 
predisposing to biphasic reactions.57   
Anaphylaxis treatment does not end with acute episode resolution in 
a healthcare facility. Patients should be discharged with epinephrine 
or an epinephrine prescription, preferably in the form of epinephrine 
auto-injectors. Patients should be given a personalized written 
anaphylaxis emergency plan that helps them recognize anaphylaxis 
symptoms, coached in using self-injectable epinephrine, and referred 
to a pediatric allergy specialist for potential trigger assessment.58 
Educational materials including emergency plans are published 
and available in Portuguese to improve anaphylaxis knowledge and 
management among patients, parents, and caregivers.59
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Long-term anaphylaxis management
Anaphylaxis education should begin prior to ED discharge and 
include a personalized written anaphylaxis emergency action 
plan. Patients at high risk for anaphylaxis may need to carry two 
epinephrine doses, for cases in which the first dose is not effectively 
administered, symptoms persist despite successful first injection, 
or patients live far from medical resource settings or experience 
biphasic anaphylaxis.60 Epinephrine auto-injectors are designed for 
self-administration or for administration by another person, but 
patients should seek prompt professional treatment immediately 
following epinephrine administration.61 It has been shown that many 
children and adolescents suffering from anaphylaxis, even associated 
with severe respiratory distress, wheezing, or loss of consciousness, 
do not use their epinephrine auto-injector, which reinforces the need 
for future information campaigns.32 
The European Academy of Allergy and Clinical Immunology (EAACI) 
guidelines refer to six absolute indications for epinephrine auto-
injector prescription:4,20 
 - Previous anaphylaxis with food, latex, or unavoidable 
triggers; 
 - Previous exercise-induced anaphylaxis; 
 - Previous idiopathic anaphylaxis; 
 - Co-existent unstable or moderate-to-severe, persistent 
asthma with food allergy; 
 - Venom allergy in adults with previous systemic reactions 
(unless receiving maintenance VIT) and children with more than 
systemic cutaneous reactions; 
 - Underlying mast cell disorders or elevated baseline serum 
tryptase concentrations together with any previous systemic 
allergic reactions to insect stings, even in VIT-treated patients.37
Anaphylaxis management plan
A personalized written anaphylaxis emergency plan should include 
avoidance advice, contact details, and an anaphylaxis emergency 
action plan with likely presenting symptoms and how to respond to 
each.37 A UK study showed that a management plan implemented in 
a Pediatric Allergy Clinic had a positive effect on parental knowledge 
of avoidance measures and emergency reaction treatment.62
Focused preventive measures after diagnostic workup may reduce 
risk of new episodes in susceptible individuals. Venom immunotherapy 
is recommended for patients who experienced a systemic reaction 
after an insect sting and shown evidence of specific IgE to venom 
allergens.63 In pediatric patients, protection efficacy has been shown 
to be as high as 98%.58 At present, the only measure for food-induced 
anaphylaxis is strict dietary avoidance, but therapies to prevent 
food-induced anaphylaxis are under investigation.61 In selected 
patients, desensitization or oral immunotherapy with food allergens 
as milk, egg, peanut, or tree nut confirm that incremental dosing 
leads to clinical desensitization and possibly to immune tolerance 
development.41 In latex allergy, precautions should be taken during 
medical and surgical treatments. The possibility of cross-reactivity 
with fruits or other foods should also be investigated.64 In exercise-
induced anaphylaxis, strict avoidance of the relevant co-trigger 
(as food or NSAIDs) should be recommended three hours prior to 
planned exercise and one hour following exercise. In physically active 
young children, it may be necessary to totally eliminate the food from 
diet to achieve successful separation of food ingestion and exercise.65 
Information about future anaphylaxis risk may lead to stress and 
anxiety and this should be addressed as part of educational training 
to minimize the impact on patients’ quality of life, as some patients 
may require psychological intervention.66
CONCLUSION
Anaphylaxis is the cornerstone of an acute allergic reaction requiring 
immediate treatment. Although still a rare clinical condition, it seems 
to be on the rise among both adults and children. Young children 
seem to be particularly affected and males have an increased risk 
during childhood. In pediatric reports, foods are the main triggers, 
followed by drugs and insect venoms. Diagnosis is based on a 
plethora of signs and symptoms that can be easily missed in young 
patients. Immediate treatment should comprise IM epinephrine, but 
a personalized action plan must be designed for each patient after 
acute phase resolution to enable prompt recognition and treatment 
of future episodes. All patients should be assessed to identify triggers 
and implement preventive avoidance measures.
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